S2 Ep59: Taletrectinib Takes Aim: A New Chapter in ROS1-Positive NSCLC

from Pharmacy Focus · host Pharmacy Times

Kevin Chen, PharmD, MS, BCOP, CPP, and Amanda Cass, PharmD, BCPS, BCOP, share key insights about ROS1, non-small cell lung cancer, and the new approved drug taletrectinib.

Episode metadata supplied by the publisher feed · Published Jul 30, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

S2 Ep59: Taletrectinib Takes Aim: A New Chapter in ROS1-Positive NSCLC

0:00 33:45

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Pharmacy Focus?

This episode is 33 minutes long.

When was this Pharmacy Focus episode published?

This episode was published on July 30, 2025.

Can I download this Pharmacy Focus episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!